GlassScriptPhysician profile
Michael D Radosevich
NPI 1932136827
$1,818.39
in general payments reported to CMS, 2019-2025
13 companies · $290 in 2025
The $290 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.39 · 2020: $118 · 2021: $328 · 2022: $161 · 2023: $250 · 2024: $598 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,138.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $406.24 | 2023-2025 | Izervay |
| Genentech USA, INC. | $358.98 | 2019-2025 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $296.55 | 2019-2025 | Eylea Hd, Eylea |
| Alimera Sciences, INC. | $265.82 | 2020-2024 | Yutiq, Iluvien |
| Abbvie INC. | $150.41 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $108.65 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $61.74 | 2023-2025 | Syfovre |
| Ani Pharmaceuticals, INC. | $52.29 | 2025 | Yutiq |
| Biogen, INC. | $44.91 | 2022-2023 | |
| Sandoz INC. | $23.81 | 2024 | Cimerli |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $17.74 | 2020 | |
| Coherus Oncology, INC. | $15.87 | 2023 | |
| Bausch & Lomb Americas INC. | $15.38 | 2024 | Xipere |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Radosevich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.